What is HC Wainwright’s Forecast for XFOR FY2028 Earnings?

X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) – Investment analysts at HC Wainwright lowered their FY2028 earnings estimates for X4 Pharmaceuticals in a research note issued on Thursday, March 27th. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $0.00 per share for the year, down from their previous estimate of $0.02. HC Wainwright has a “Buy” rating and a $1.50 price target on the stock. The consensus estimate for X4 Pharmaceuticals’ current full-year earnings is ($0.68) per share. HC Wainwright also issued estimates for X4 Pharmaceuticals’ FY2029 earnings at $0.15 EPS.

X4 Pharmaceuticals (NASDAQ:XFOR) last released its quarterly earnings results on Tuesday, March 25th. The company reported ($0.20) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.17) by ($0.03). The business had revenue of $1.43 million during the quarter, compared to analyst estimates of $1.07 million.

Separately, Cantor Fitzgerald reissued an “overweight” rating and issued a $3.00 price target on shares of X4 Pharmaceuticals in a research note on Wednesday.

X4 Pharmaceuticals Price Performance

Shares of X4 Pharmaceuticals stock opened at $0.27 on Friday. The company has a debt-to-equity ratio of 1.26, a current ratio of 4.89 and a quick ratio of 4.80. X4 Pharmaceuticals has a one year low of $0.24 and a one year high of $1.60. The stock has a market capitalization of $47.08 million, a P/E ratio of -3.01 and a beta of 0.39. The business’s 50 day simple moving average is $0.44 and its two-hundred day simple moving average is $0.52.

Hedge Funds Weigh In On X4 Pharmaceuticals

Hedge funds and other institutional investors have recently bought and sold shares of the business. Point72 Asset Management L.P. boosted its position in X4 Pharmaceuticals by 4.0% during the fourth quarter. Point72 Asset Management L.P. now owns 650,000 shares of the company’s stock worth $477,000 after purchasing an additional 24,948 shares in the last quarter. Deutsche Bank AG boosted its position in shares of X4 Pharmaceuticals by 559.6% during the 4th quarter. Deutsche Bank AG now owns 267,628 shares of the company’s stock valued at $195,000 after acquiring an additional 227,051 shares during the last quarter. Cantor Fitzgerald L. P. acquired a new position in X4 Pharmaceuticals in the 4th quarter valued at about $30,000. Bank of America Corp DE grew its position in X4 Pharmaceuticals by 20.3% in the fourth quarter. Bank of America Corp DE now owns 133,502 shares of the company’s stock worth $98,000 after acquiring an additional 22,485 shares during the period. Finally, Acorn Capital Advisors LLC acquired a new stake in shares of X4 Pharmaceuticals during the 4th quarter worth about $5,363,000. Institutional investors and hedge funds own 72.03% of the company’s stock.

Insider Buying and Selling at X4 Pharmaceuticals

In related news, CFO Adam S. Mostafa sold 74,773 shares of the business’s stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $33,647.85. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Paula Ragan sold 76,473 shares of the firm’s stock in a transaction dated Friday, January 24th. The shares were sold at an average price of $0.45, for a total value of $34,412.85. Following the sale, the chief executive officer now directly owns 1,087,386 shares in the company, valued at approximately $489,323.70. The trade was a 6.57 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 202,663 shares of company stock worth $91,198 over the last quarter. Insiders own 1.62% of the company’s stock.

About X4 Pharmaceuticals

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.